Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab on Platelet Reactivity in DM Patients After PCI
NCT03258281Phase 4Terminated
- Sponsor
- Inova Health System
- Start
- May 2018
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in dyslipidemia, sponsored by Inova Health System. Started May 2018; status: terminated.
02
Drugs
evolocumab
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03258281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258281.